PubMed Journals Articles About "Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis" RSS

06:55 EDT 19th March 2018 | BioPortfolio

Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis articles that have been published worldwide.

More Information about "Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis" on BioPortfolio

We have published hundreds of Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis news stories on BioPortfolio along with dozens of Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis Clinical Trials and PubMed Articles about Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis Companies in our database. You can also find out about relevant Study Evaluating Workload, Clinical And Therapeutic Management Of Psoriatic Arthritis Drugs and Medications on this site too.

Showing "Study Evaluating Workload Clinical Therapeutic Management Psoriatic Arthritis" PubMed Articles 1–25 of 88,000+

Progress in genetic research on psoriatic arthritis.

Psoriatic arthritis is a form of inflammatory arthritis found among patients with psoriasis, which can lead to pain, swelling or stiffness in one or more joints and even movement disorders. Epidemiological studies have shown a higher heritability for psoriatic arthritis compared with psoriasis vulgaris. With the evolvement of DNA sequencing, many genes have been associated with psoriasis vulgaris and psoriatic arthritis, which included MHC, TNF, LCE, IL23R, IL12B, TRAF3IP2 and TNFAIP3, though some, such as ...

Consensus on the management of patients with psoriatic arthritis in a dermatology setting.

Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis (PsO). Early diagnosis and prompt therapeutic intervention are crucial for limiting PsA progression and prevention of disability. Dermatologists are in a privileged position to detect early PsA. The management of patients with PsA in the dermatology setting is widely variable.

A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis.

The aim of this study was to systemically review the efficacy and safety of inhibitors of interleukin 6 (IL-6): clazakizumab, IL-12/23: ustekinumab, and IL-17A: secukinumab, brodalumab, and ixekizumab in psoriatic arthritis (PsA).

Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients.

In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets.

Psoriatic arthritis: new evidence for old concepts.

The review gives an updated overview of some of the new concepts in the management of psoriatic arthritis (PsA): early diagnosis, remission as an objective, treat-to-target, and treatment guidelines.

Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.

To introduce a novel pre-clinical animal model of psoriatic arthritis, R26STAT3CCD4Cre mice, and investigate the role of Th17 cytokines in the disease pathogenesis.

Cardiometabolic Disorders in Psoriatic Disease.

Patients with psoriasis and psoriatic arthritis, collectively termed psoriatic disease (PsD), are at an increased risk of developing cardiovascular diseases (CVD). The purpose if this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of CVD in psoriatic patients and approaches to improve the management of these comorbidities.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.

Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs).

Outcome measures of disease activity in inflammatory arthritis.

The most common types of chronic inflammatory arthritis are rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. In order to assess the activity of these diseases and tailor therapy, several outcome measures have been developed. They include composite scores based on clinical findings, biochemical markers and patient questionnaires. This article discusses the most commonly used outcome measures and looks at their limitations in quantifying the complex clinical features of different types of...

Comprehensive evaluation of finger flexor tendon entheseal soft tissue and bone changes by ultrasound can differentiate psoriatic arthritis and rheumatoid arthritis.

To determine whether a detailed sonographic evaluation of the hand flexor tendon compartment could help differentiate between psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

"STATus of STAT3 in Psoriatic Arthritis."

Joint disease and enthesopathy are seen in about one-third of patients with psoriasis and are usually preceded by the cutaneous manifestations of psoriasis. The relationships between the pathogenesis of psoriatic skin disease and the pathogenesis of psoriatic arthritis have not been defined, however, and the central question as to whether psoriatic skin disease initiates development of joint disease remains unresolved. This article is protected by copyright. All rights reserved.

Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab.

Ustekinumab (UST) is a fully human immunoglobulin G1 monoclonal antibody approved for treating moderate to severe psoriasis and, more recently, psoriatic arthritis (PsA) as well. However, information regarding its clinical usefulness in a real-world setting is scarce. We aimed to evaluate the effectiveness and safety of UST in a real-world clinical setting.

Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis and psoriatic arthritis in Sweden: a population-based cohort study.

Rheumatoid arthritis (RA) is a risk factor for tuberculosis (TB), particularly following treatment with biologicals. Since these therapies are increasingly used in ankylosing spondylitis (AS), other types of spondyloarthritis (SpA) and psoriatic arthritis (PsA), we investigated the corresponding TB risks in these patients.

Trial Characteristics as Contextual Factors when Evaluating Targeted Therapies in Patients with Psoriatic Disease: A Meta-Epidemiological Study.

To assess the importance of trial characteristics as contextual factors when evaluating treatment effect of targeted therapies for patients with psoriatic disease.

Radiographic progression is less in psoriatic arthritis achieving a good response to treatment: data using newer composite indices of disease activity.

The purpose of this study was to compare radiographic outcomes according to the magnitude of the response utilizing three new psoriatic composite disease activity measures (the Psoriatic Arthritis Disease Activity Score (PASDAS), the GRAPPA Composite Exercise (GRACE), and the Disease Activity in PsA (DAPSA). The data were taken from the GO-REVEAL dataset, a large randomised, double-blind, study which evaluated the safety and efficacy of 2 doses of the TNF inhibitor golimumab in subjects with active PsA.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study.

To evaluate minimal disease activity (MDA) among psoriatic arthritis (PsA) patients receiving secukinumab through 2 years in the FUTURE 2 study (NCT01752634).

Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Psoriatic arthritis is an inflammatory arthritis without a clear etiology. Biological therapy is key for its treatment, especially in more complex patients. There are several alternatives for biological treatment, but due to its high cost, it is important to evaluate their real effectiveness.

C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.

Complement activation correlates to rheumatoid arthritis disease activity, and increased amounts of the complement split product C5a is observed in synovial fluids from rheumatoid arthritis patients. Blockade of C5a or its receptor (C5aR) is efficacious in several arthritis models. The aim of this study was to investigate the role of C5a and C5aR in human rheumatoid arthritis and psoriatic arthritis-both with respect to expression and function. Synovial fluid, blood and synovial samples were obtained from r...

Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.

Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Psoriasis Area and Severity Index (PASI) 75 and ...

Biologics in inflammatory and immunomediated arthritis.

Biologic drugs, introduced in clinical practice almost twenty years ago, represent nowadays a prominent treatment option in patients with chronic inflammatory arthritis, such as Rheumatoid Arthritis, Psoriatic Arthritis and Spondyloarthritis, that include ankylosing spondylitis and non-radiographic axial spondyloarthritis.

Psoriatic Arthritis in Nigeria: Case Series and Literature Review.

Psoriatic arthritis (PsA) is an extracutaneous manifestation of psoriasis occurring in 6% to 42% of patients. Both conditions are common among whites but rarely reported among black Africans.Few African studies, however, have reported PsA frequencies of 0% to 4.6%, with a previous case report of 2 patients from a Nigerian rheumatology clinic.

Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study.

Smoking is associated with an increased risk of psoriatic arthritis (PsA) in the general population, but not among patients with psoriasis. We sought to clarify the possible methodological mechanisms behind this paradox.

Real-world burden of comorbidities in US patients with psoriatic arthritis.

We assessed comorbidities associated with psoriatic arthritis in a broad cohort of US-insured adult patients using the Truven Health Analytics MarketScan Database.

Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis.

Fatigue is a significant issue in psoriatic arthritis. The objective was to assess the effect of biological disease modifying antirheumatic drugs and apremilast on fatigue in psoriatic arthritis randomised controlled trials and to compare this effect with the effect in the same trials, on pain, through a systematic literature review and meta-analysis.

Quick Search